Faridoxorubicin

Faridoxorubicin (AVA-6000) is a prodrug that targets fibroblast activation protein alpha (FAPα) . It releases active doxorubicin through FAPα-mediated cleavage, enhancing drug exposure within tumors while reducing cardiac toxicity. Faridoxorubicin holds potential for research in solid tumors, such as liver metastases from colorectal cancer.

OC=1C2=C([C@@H](O[C@H]3C[C@H](NC(=O)[C@H]4N(C([C@H](NC(=O)C=5C=CN=CC5)C)=O)CCC4)[C@H](O)[C@H](C)O3)C[C@@](C(CO)=O)(O)C2)C(O)=C6C1C(=O)C=7C(C6=O)=C(OC)C=CC7